OR7E37P: A Potential Drug Target and Biomarker (G100506759)
OR7E37P: A Potential Drug Target and Biomarker
OR7E37P is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. Its full name is ornitinellin-conjugated retinol dehydrogenase 37P, and it is a member of the superfamily of NAD+-dependent enzymes, known as NAD+-dependent enzymes. OR7E37P is unique because it is a potent inhibitor of the enzyme cyclic ADP-ribose synthase (CARDS), which is involved in the production of reactive oxygen species (ROS) that can cause damage to tissues and contribute to various diseases, including cancer and neurodegenerative disorders.
In recent years, researchers have been interested in investigating the potential therapeutic benefits of drugs that target OR7E37P because of its unique mechanism of action. OR7E37P is a strong candidate for drug development because it is a versatile target that can be modulated with various chemical compounds, making it an attractive target for drug researchers.
One of the advantages of OR7E37P is its expression in a variety of tissues, which makes it an attractive target for drug development. OR7E37P is expressed in the brain, heart, liver, and kidneys, which are all critical organs for the proper functioning of the body. Therefore, drugs that can modulate OR7E37P levels in these tissues could have a broad therapeutic impact on various diseases.
Another advantage of OR7E37P is its unique function as an inhibitor of CARDS. CARDS is an enzyme that is involved in the production of ROS, which can contribute to the development of various diseases, including cancer and neurodegenerative disorders. By inhibiting CARDS, OR7E37P can reduce the production of ROS, which can have a beneficial effect on the body.
In addition, OR7E37P is a good candidate for drug development because of its high potency. Studies have shown that OR7E37P is a strong inhibitor of CARDS, with a potency that is similar to that of the drug Kimodulcin. This means that a drug that is as effective as Kimodulcin could be used to treat diseases that are caused by the production of ROS.
Finally, OR7E37P is a unique target because of its expression in the brain. OR7E37P is highly expressed in the brain, and it is involved in the development and maintenance of the brain. Therefore, drugs that can modulate OR7E37P levels in the brain could have a unique therapeutic impact on neurodegenerative disorders.
In conclusion, OR7E37P is a protein that is expressed in various tissues of the body and is involved in the production of ROS. Its unique function as an inhibitor of CARDS makes it an attractive target for drug development. Its high potency and expression in the brain make it a good candidate for drug development. Further research is needed to determine the full therapeutic potential of OR7E37P as a drug target.
Protein Name: Olfactory Receptor Family 7 Subfamily E Member 37 Pseudogene
More Common Targets
OR7E41P | OR7E47P | OR7E5P | OR7E62P | OR7E84P | OR7E85BP | OR7E87P | OR7E91P | OR7E94P | OR7G1 | OR7G2 | OR7G3 | OR7M1P | OR8A1 | OR8B12 | OR8B2 | OR8B3 | OR8B4 | OR8B6P | OR8B7P | OR8B8 | OR8D1 | OR8D2 | OR8D4 | OR8F1P | OR8G1 | OR8G2P | OR8G3P | OR8G5 | OR8G7P | OR8H1 | OR8H2 | OR8H3 | OR8I2 | OR8J1 | OR8J3 | OR8K1 | OR8K3 | OR8K5 | OR8S1 | OR8U1 | OR8U3 | OR8U8 | OR9A1P | OR9A2 | OR9A4 | OR9G1 | OR9G4 | OR9G9 | OR9H1P | OR9I1 | OR9K2 | OR9Q1 | OR9Q2 | ORAI1 | ORAI2 | ORAI3 | ORC1 | ORC2 | ORC3 | ORC4 | ORC5 | ORC6 | Orexin receptor | Organic anion transporters (OATs) | Organic cation transporter | Origin recognition complex | ORM1 | ORM2 | ORMDL1 | ORMDL2 | ORMDL3 | OS9 | OSBP | OSBP2 | OSBPL10 | OSBPL11 | OSBPL1A | OSBPL2 | OSBPL3 | OSBPL5 | OSBPL6 | OSBPL7 | OSBPL8 | OSBPL9 | OSCAR | OSCP1 | OSER1 | OSER1-DT | OSGEP | OSGEPL1 | OSGEPL1-AS1 | OSGIN1 | OSGIN2 | OSM | OSMR | OSMR-DT | OSR1 | OSR2 | OST4
